IBDEI2JA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,42985,1,4,0)
 ;;=4^E10.40
 ;;^UTILITY(U,$J,358.3,42985,2)
 ;;=^5002604
 ;;^UTILITY(U,$J,358.3,42986,0)
 ;;=E10.42^^164^2060^84
 ;;^UTILITY(U,$J,358.3,42986,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42986,1,3,0)
 ;;=3^DM Type 1 w/ DM Polyneuropathy
 ;;^UTILITY(U,$J,358.3,42986,1,4,0)
 ;;=4^E10.42
 ;;^UTILITY(U,$J,358.3,42986,2)
 ;;=^5002606
 ;;^UTILITY(U,$J,358.3,42987,0)
 ;;=E10.43^^164^2060^78
 ;;^UTILITY(U,$J,358.3,42987,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42987,1,3,0)
 ;;=3^DM Type 1 w/ DM Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,42987,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,42987,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,42988,0)
 ;;=E10.51^^164^2060^82
 ;;^UTILITY(U,$J,358.3,42988,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42988,1,3,0)
 ;;=3^DM Type 1 w/ DM Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,42988,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,42988,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,42989,0)
 ;;=E10.52^^164^2060^83
 ;;^UTILITY(U,$J,358.3,42989,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42989,1,3,0)
 ;;=3^DM Type 1 w/ DM Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,42989,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,42989,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,42990,0)
 ;;=E10.610^^164^2060^80
 ;;^UTILITY(U,$J,358.3,42990,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42990,1,3,0)
 ;;=3^DM Type 1 w/ DM Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,42990,1,4,0)
 ;;=4^E10.610
 ;;^UTILITY(U,$J,358.3,42990,2)
 ;;=^5002613
 ;;^UTILITY(U,$J,358.3,42991,0)
 ;;=E10.620^^164^2060^79
 ;;^UTILITY(U,$J,358.3,42991,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42991,1,3,0)
 ;;=3^DM Type 1 w/ DM Dermatitis
 ;;^UTILITY(U,$J,358.3,42991,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,42991,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,42992,0)
 ;;=E10.621^^164^2060^85
 ;;^UTILITY(U,$J,358.3,42992,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42992,1,3,0)
 ;;=3^DM Type 1 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,42992,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,42992,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,42993,0)
 ;;=E10.622^^164^2060^90
 ;;^UTILITY(U,$J,358.3,42993,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42993,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,42993,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,42993,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,42994,0)
 ;;=E10.630^^164^2060^89
 ;;^UTILITY(U,$J,358.3,42994,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42994,1,3,0)
 ;;=3^DM Type 1 w/ Peridontal Disease
 ;;^UTILITY(U,$J,358.3,42994,1,4,0)
 ;;=4^E10.630
 ;;^UTILITY(U,$J,358.3,42994,2)
 ;;=^5002619
 ;;^UTILITY(U,$J,358.3,42995,0)
 ;;=E10.641^^164^2060^87
 ;;^UTILITY(U,$J,358.3,42995,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42995,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,42995,1,4,0)
 ;;=4^E10.641
 ;;^UTILITY(U,$J,358.3,42995,2)
 ;;=^5002621
 ;;^UTILITY(U,$J,358.3,42996,0)
 ;;=E10.649^^164^2060^88
 ;;^UTILITY(U,$J,358.3,42996,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42996,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,42996,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,42996,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,42997,0)
 ;;=E10.65^^164^2060^86
 ;;^UTILITY(U,$J,358.3,42997,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42997,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,42997,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,42997,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,42998,0)
 ;;=E11.40^^164^2060^95
 ;;^UTILITY(U,$J,358.3,42998,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42998,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathy,Unspec
